## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

## **SCHEDULE 14A**

(RULE 14a-101)

### **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant  $\boxtimes$ 

Filed by a Party other than the Registrant  $\Box$ 

Check the appropriate box:

- □ Preliminary Proxy Statement.
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)).
- □ Definitive Proxy Statement.
- ☑ Definitive Additional Materials.
- □ Soliciting Material Pursuant to §240.14a-12.

## vTv Therapeutics Inc.

(Name of Registrant as Specified in its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- $\boxtimes$  No fee required.
- $\Box$  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  - (2) Aggregate number of securities to which transaction applies:
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

 $\hfill\square$  Fee paid previously with preliminary materials.

□ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:

(4) Date Filed:



# Important Notice Regarding the Availability of Proxy Materials for vTv Therapeutics Inc.

Stockholders Meeting to be held on May 03, 2021 For Stockholders as of March 08, 2021

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials go to: www.proxydocs.com/VTVT

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

CONTROL NUMBER

#### For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/VTVT



Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.

if you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's shareholder meeting, you must make this request on or before April 23, 2021

To order paper materials, use one of the following methods.







When requesting via the internet or telephone you will need the 12 digit control number located in the shaded box above.

#### vTv Therapeutics Inc. Meeting Information

Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Meeting Type: Annual Meeting of Stockholders

Date: Monday, May 03, 2021 Time: 09:00 AM, Local Time

Place: Annual Meeting to be held live via the Internet - please visit

www.proxydocs.com/VTVT for more details.

You must pre-register to attend the meeting online and/or participate at the email address indicated.

SEE REVERSE FOR FULL AGENDA

Copyright © 2021 Mediant Communications Inc. All Rights Reserved

requesting material.

### vTv Therapeutics Inc.

#### Annual Meeting of Stockholders

#### THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL(S) 1, 2, 3.

PROPOSAL

To elect six director nominees to serve until our next annual meeting or until their successors have been elected and qualified;
1.01 Robin E. Abrams

1.02 John A. Fry

1.03 Hersh Kozlov

1.04 Richard S. Nelson

1.05 Noel J. Spiegel

1.06 Howard L. Weiner

- 2. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Class A Common Stock.
- 3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.